Skip to main content
main-content

The independent medical news service

Lung cancer

09-06-2021 | Oncology | News | Article

CheckMate 9LA update shows continued benefit of nivolumab–ipilimumab plus chemo

The addition of nivolumab plus ipilimumab to first-line chemotherapy continues to be beneficial for patients with metastatic non-small-cell lung cancer with longer follow-up, show updated phase 3 trial data.

09-06-2021 | Oncology | News | Article

CheckMate 816 surgical outcomes support neoadjuvant nivolumab in NSCLC

Adding nivolumab to neoadjuvant chemotherapy for resectable non-small-cell lung cancer is not associated with surgical delays or complications, show CheckMate 816 data presented at the 2021 ASCO Annual Meeting.

06-06-2021 | Oncology | News | Article

PACIFIC at 5 years shows ‘robust and sustained’ OS benefit with durvalumab

Five-year findings from the PACIFIC trial for patients with unresectable stage III non-small-cell lung cancer continue to show survival benefits with 1 year of durvalumab therapy versus placebo after platinum-based chemoradiotherapy.

06-06-2021 | Oncology | News | Article

Immunotherapy plus chemo may be preferable for advanced NSCLC with PD-L1 score of 1–49%

The outcomes of treatment-naïve, advanced non-small-cell lung cancer patients with tumor PD-L1 levels of 1–49% may be better with the combination of chemotherapy and immunotherapy than immunotherapy alone, suggests a pooled analysis by the US FDA.

04-06-2021 | Oncology | News | Article

Adjuvant atezolizumab delays recurrence in early-stage NSCLC patients

People with stage II–IIIA non-small-cell lung cancer derive a significant disease-free survival benefit from adjuvant treatment with atezolizumab versus best supportive care, according to phase 3 trial results.

03-06-2021 | Oncology | News | Article

Sotorasib approved for KRAS-mutated NSCLC in USA

More information on this announcement available here

01-06-2021 | Oncology | News | Article

Tislelizumab benefit demonstrated in advanced nonsquamous NSCLC

The addition of tislelizumab to first-line chemotherapy significantly improves the progression-free survival of patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer, indicate phase 3 trial results.

28-05-2021 | Oncology | News | Article

EMA recommends cemiplimab for first-line NSCLC treatment

Read more on this decision here

25-05-2021 | Oncology | News | Article

FDA approves amivantamab for advanced NSCLC with EGFR exon 20 insertions

Click through for more details

17-05-2021 | Oncology | News | Article

Nab-paclitaxel offers alternative to docetaxel in pretreated advanced NSCLC

Nab-paclitaxel offers a similar survival benefit to docetaxel when given to previously treated patients with advanced non-small-cell lung cancer, show data from the phase 3 J-AXEL trial.

13-05-2021 | Oncology | News | Article

Real-world pneumonitis rates with pembrolizumab–chemotherapy exceed clinical trial data

A Japanese real-world study has found higher rates of pneumonitis with first-line pembrolizumab plus chemotherapy among patients with advanced nonsquamous non-small-cell lung cancer than previously reported in clinical trials.

07-05-2021 | Oncology | News | Article

Dacomitinib has ‘limited benefit’ after first-line osimertinib

Second-line dacomitinib treatment is associated with a low objective response rate among patients with EGFR-mutated non-small-cell lung cancer who progress on first-line osimertinib, report US researchers.

04-05-2021 | Oncology | News | Article

KEYNOTE-189 final analysis confirms pembrolizumab nonsquamous NSCLC benefits

The addition of pembrolizumab to pemetrexed–paclitaxel chemotherapy provides durable survival advantages for treatment-naïve patients with metastatic, nonsquamous non-small-cell lung cancer, the final protocol-specified analysis of KEYNOTE-189 has confirmed.

26-04-2021 | Oncology | News | Article

EMA recommends extending osimertinib indication

Find out more about this decision here

22-04-2021 | Oncology | News | Article

Limited evidence to link antihypertensive use to cancer

An extensive meta-analysis of individual participant data has not found consistent evidence to indicate that antihypertensive use is associated with an increased risk for cancer.

19-04-2021 | Oncology | News | Article

Chemoimmunotherapy may be preferable for KRAS wild-type NSCLC

Chemoimmunotherapy may be a better option than immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer patients with high PD-L1 expression and no KRAS mutations, indicate findings.

16-04-2021 | Oncology | News | Article

ESMO issues recommendations for SCLC management

More information on these Clinical Practice Guidelines available here

16-04-2021 | Oncology | News | Article

Outliers in link between obesity and poor cancer survival reinforced in meta-analysis

Individuals with obesity tend to have worse cancer survival outcomes than those without obesity, unless they have lung cancer, renal cell carcinoma, or melanoma, show findings of a systematic review and meta-analysis.

15-04-2021 | Oncology | News | Article

Sintilimab could be a viable second-line option for advanced squamous NSCLC

Patients with advanced squamous non-small-cell lung cancer derive a significant overall survival benefit from second-line treatment with sintilimab versus docetaxel, suggest results from the Chinese ORIENT-3 trial.

15-04-2021 | Oncology | News | Article

Tislelizumab offers improved outcomes over docetaxel in advanced NSCLC

The anti-PD-1 antibody tislelizumab may improve outcomes relative to docetaxel as a second- or third-line therapy for people with advanced non-small-cell lung cancer, regardless of histology or PD-L1 expression levels, researchers report.

Image Credits